Amicus Therapeutics is the leading bioengineers of advanced and customized therapies, specifically rare and orphan diseases.

It is a biopharmaceutical company that is based in New Jersey and expanded to San Diego in 2008 to a second location.

The products of Amicus Therapeutics are pharmaceuticals, drugs.


Biopharmaceuticals, by general definition, is any drug product (pharmaceutical) that is extracted from a biological source. If it is semi-synthesized or manufactured in a biological source, then it also qualifies as a biopharmaceutical.


Biopharmaceuticals means that some element of engineering or manipulation is involved. These can be employed to treat a wide array of pediatric and rare life-threatening diseases.

Amicus Therapeutics belief statement is long and extensive with more than fifteen different pledges that honor the trust and relationship between employee, company, co-workers and consumers. The pledges are detailed and emotional, more so passionate than one would ordinarily see in a traditional company belief statement. Some of the beliefs held by Amicus Therapeutics include:


  • Passion
  • Encouragement
  • Work hard and take smart risks
  • No lying, cheating or stealing


John F. Crowley, current Chief Executive Officer of Amicus Therapeutics Inc, offers a welcoming introduction on the company website.


The company list the three traits that all patients have. The point of mentioning this important and crucial fact is what truly makes this biotech company unique ( Each investable program that Amicus contributes to has to have the three following factors:


  • Deadly or devastating disorder, rare diseases
  • Technology is cutting edge and latest available
  • Only if the results from previous data show that patients lives will improve


Crowley aims to provide patients with an extra layer of care, emphasizing the personal aspects of the company mission statement. Crowley emphasizes his ability to empathize with the patient, to be able to offer the best patient experience, personally tailored towards the patients, and caregivers, of those living – and surviving with diseases (